Printer Friendly


XENiOS i-cor is the first to offer Synchronized Cardiac Assist, which provides cardiac support in harmony with each heartbeat, designed to unite myocardial protection with organ perfusion

XENIOS has enrolled the first patient in the SynCor clinical trial of its CE-marked i-cor Synchronized Cardiac Assist System for treating cardiogenic shock.

The SynCor trial is a prospective, non-randomized, multi- center, open-label observational study of the safety and performance of the i-cor System in 45 consecutively enrolled patients with cardiogenic shock or in high-risk percutaneous intervention procedures in the cardiac catheterization lab.

The i-cor Synchronized Cardiac Assist System represents an entirely new era for percutaneous circulatory support in heart failure, said Georg Matheis, MD, Managing Director of XENiOS.

Synchronized Cardiac Assist overlays or superimposes a physiological pulse wave onto the patient's weakened pulse and is designed to be a less-invasive treatment than the current standard while using a more physiological treatment essential to endothelial function, which ensures adequate tissue perfusion in the organs. Maintaining organ function serves to prevent multi-organ failure and to improve clinical outcomes. The oxygenating power of the i-cor Synchronized Cardiac System allows for a reduction of invasiveness compared to standard care by reducing blood flow and thus reducing cannula size. As a result, i-cor is designed to offer physiological circulatory support, protection, and safety during interventions in the cardiac cath lab, as well as for the management of cardiogenic shock in the ICU and the cardiac cath lab.

The i-cor system is a small extracorporeal pump that is synchronized to the heart beat (the ECG) so that augmentation of cardiac output with well-oxygenated blood occurs during diastole. The i-cor system, which provides Synchronized Cardiac Assist, combines the best elements of cardiac assist and augmented cardiac function associated with IABP and percutaneous ventricular assist devices but does not increase left ventricular afterload or ventricular work.

The i-cor Synchronized Cardiac Assist device reduces the mechanical and energy required by the heart to generate adequate blood pressure and blood flow to perfuse the tissues of each organ, added Dr. Matheis. The purpose of the SynCor trial is to study the safety and performance of the i-cor Synchronized Cardiac Assist device in order to optimize the performance of our device in the setting of cardiogenic shock following or associated with cardiac ischemic events, as well as in the setting of high-risk percutaneous intervention procedures in the cardiac catheterization lab. We look forward to reporting the results of this study.


XENIOS AG is a privately held medical technology company that is comprised of two product brands, novalung and i cor, that run on a single XENIOS platform. XENIOS novalung offers the full spectrum of extrapulmonary lung support. XENIOS i-cor is focused on heart therapies. The XENiOS platform is designed for physicians to treat the same patient who either has certain singular lung or heart issues, or has concomitant lung and heart issues, with one platform of minimally invasive products that do not require mechanical ventilation, sedation, and immobility. XENIOS AG is the only company that can make this claim.

For more information, visit or call 508/359-4005, ext. 108.
COPYRIGHT 2016 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Biotech Equipment Update
Article Type:Clinical report
Date:May 1, 2016

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters